Evidence map›Paper›PMID 33067265›Full record

ArticleCancer research2021

RNA-Binding RING E3-Ligase DZIP3/hRUL138 Stabilizes Cyclin D1 to Drive Cell-Cycle and Cancer Progression.

Srinivasa P Kolapalli, Rinku Sahu, Nishant R Chauhan, Kautilya K Jena, Subhash Mehto, Saroj K Das, Ashish Jain, Manaswini Rout, Rupesh Dash, Rajeeb K Swain and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Advances of E3 ligases in lung cancer.Biochemistry and biophysics reports · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis.Frontiers in cell and developmental biology · 2022
    Review
  20. Pharmacogenomics and personalized medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Srinivasa P Kolapalli *Cell and Cancer Biology Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India.ORCID https://orcid.org/0000-0003-2209-2519
Rinku Sahu *Cell and Cancer Biology Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India.
Nishant R Chauhan *Cell and Cancer Biology Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India.ORCID https://orcid.org/0000-0002-9137-6024
Kautilya K Jena *Cell and Cancer Biology Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India.ORCID https://orcid.org/0000-0002-7568-1555
Subhash MehtoCell and Cancer Biology Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India.ORCID https://orcid.org/0000-0002-5351-7850
Saroj K DasCentre for Biotechnology, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India.ORCID https://orcid.org/0000-0002-5717-5333
Ashish JainCentre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0001-6549-2788
Manaswini RoutVascular Biology Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India.
Rupesh DashGene Therapy and Cancer Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India.
Rajeeb K SwainVascular Biology Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India.
David Y LeeDepartment of Internal Medicine, Radiation Oncology, and University of New Mexico Comprehensive Cancer Center, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Tor Erik RustenCentre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Santosh ChauhanCell and Cancer Biology Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India. schauhan@ils.res.in swaticchauhan09@gmail.com.ORCID https://orcid.org/0000-0001-9167-5107
Swati ChauhanGene Therapy and Cancer Lab, Institute of Life Sciences, Bhubaneswar, Odisha, India. schauhan@ils.res.in swaticchauhan09@gmail.com.ORCID https://orcid.org/0000-0002-9137-6024
Institute of Life Sciences · INOslo University Hospital · NONew Mexico Cancer Center · USSiksha O Anusandhan University · IN

Funding

DBT-Wellcome Trust India Alliance IA/I/15/2/502071Wellcome Trust
6 · The paper itself

Abstract

DZIP3/hRUL138 is a poorly characterized RNA-binding RING E3-ubiquitin ligase with functions in embryonic development. Here we demonstrate that DZIP3 is a crucial driver of cancer cell growth, migration, and invasion. In mice and zebrafish cancer models, DZIP3 promoted tumor growth and metastasis. In line with these results, DZIP3 was frequently overexpressed in several cancer types. Depletion of DZIP3 from cells resulted in reduced expression of Cyclin D1 and a subsequent G

Indexed as

Gene Expression Regulation, NeoplasticRNA StabilityAnimalsApoptosisBiomarkers, TumorBreast NeoplasmsCell MovementCell ProliferationCyclin D1FemaleHumansLung NeoplasmsMiceMice, Inbred BALB CMice, NudePhosphorylationBiomarkers, TumorCCND1 protein, humanCyclin D1DZIP3 protein, humanRNA-Binding ProteinsUbiquitin-Protein Ligases

Identifiers

PMID33067265
PMCPMC7116596
OpenAlexW3093425526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.